Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

por Peng, Xiaomei, Ascher-Svanum, Haya, Faries, Douglas, Conley, Robert R, Schuh, Kory J
Publicado 2011

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

por Chen, Jian, Ascher-Svanum, Haya, Nyhuis, Allen W, Case, Michael G, Phillips, Glenn A, Schuh, Kory J, Hoffmann, Vicki Poole
Publicado 2011

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

por Upadhyaya, Himanshu P., Desaiah, Durisala, Schuh, Kory J., Bymaster, Frank P., Kallman, Mary J., Clarke, David O., Durell, Todd M., Trzepacz, Paula T., Calligaro, David O., Nisenbaum, Eric S., Emmerson, Paul J., Schuh, Leslie M., Bickel, Warren K., Allen, Albert J.
Publicado 2013